Latest Kidney Cancer News
Kidney Cancer News elsewhere on the Web
Renal cell carcinoma (RCC) is a malignancy that makes up 3% of adult cancers and 20%-30% of patients were diagnosed with metastatic RCC in the beginning, whi...
Yousef Zakharia, MD, discusses the long-term benefits of nivolumab plus ipilimumab according to risk status in clear cell renal cell carcinoma.
In patients with RCC, exceptional response to immunotherapy may be related to clonal neoantigen-driven cytotoxic T-cell responses, among other factors.
Toni Choueiri, MD, discusses the unique features of NKT2152, the agent’s safety profile in RCC, and future research directions across GU oncology.
Nazli Dizman, MD, explains the rationale for evaluating the impact of CBM588 on the gut microbiome in patients with metastatic RCC.
The following is a summary of “Clinical significance and pro-oncogenic function of DBF4 in clear cell renal cell carcinoma,” published in the January 2025...
During a Case-Based Roundtable® event, Kathryn E. Beckermann, MD, PhD, discussed second-line regimens with event participants depending on their own practice and trial data for a patient with clear cell renal cell carcinoma.
David A. Braun, MD, PhD, discusses future directions for research into protein glycosylation as a biomarker of response in renal cell carcinoma.
Dr. David A Braun delved into detail on the molecular factors driving exceptional responses to immunotherapy in metastatic clear cell renal cell carcinoma.
Correction: BEX4 inhibits the progression of clear cell renal cell carcinoma by stabilizing SH2D4A, which is achieved by blocking SIRT2 activity.
No results found.
Articles from Kidney Cancer UK
No results found.
No results found.